Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
0.2140
-0.0040 (-1.83%)
At close: Nov 13, 2026, 4:00 PM EST
0.2037
-0.0103 (-4.81%)
After-hours: Nov 13, 2026, 7:33 PM EST
Acumen Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
61
Market Cap
15.48M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
ABOS News
- 13 days ago - ProMIS Neurosciences price target lowered to $15 from $29 at Roth Capital - TheFly
- 13 days ago - Acumen downgraded to Neutral from Buy at Lucid Capital - TheFly
- 13 days ago - Acumen price target lowered to $1 from $8 at BTIG - TheFly
- 13 days ago - Acumen downgraded to Underperform from Buy at BofA - TheFly
- 16 days ago - Acumen downgraded to Underweight from Overweight at Cantor Fitzgerald - TheFly
- 16 days ago - Acumen downgraded to Neutral from Buy at Citi - TheFly
- 16 days ago - Acumen downgraded to Hold from Buy at Stifel - TheFly
- 16 days ago - Acumen reports ALTITUDE-AD clinical trial did not meet primary endpoint - TheFly